Risk of myocardial infarction in Dutch patients following discharge for total hip/knee replacement and matched controls: a population-based cohort study

C Klop¹, F de Vries¹–³*, A Lalmohamed¹, HGM Leufkens¹, JWJ Bijlsma⁴, PMJ Welsing⁴,⁵

Abstract

Introduction
Total joint replacement surgery of the hip and knee has been associated with an increased risk of acute myocardial infarction. However, this risk has not been compared with matched controls without surgery after discharge from the hospital. The aim of this study was to estimate the risk of myocardial infarction in Dutch patients following discharge for total hip/knee replacement and matched controls.

Materials and methods
A population-based retrospective cohort study was conducted with the Dutch PHARMO Record Linkage System. All patients with a primary elective total hip replacement (n = 13,952) or total knee replacement (n = 8239) between 2000 and 2009 were selected, and matched to 47,864 controls (no total hip replacement) by age, sex and geographical location. Time-dependent Cox regression was used to derive disease- and medication-adjusted (adj.) hazard ratios for a readmission due to acute myocardial infarction.

Results
The mean age of patients who sustained total hip replacement surgery was 68.5 years (standard deviation: 10.1), which was similar to patients who sustained total knee replacement surgery (68.4 years, standard deviation: 9.9). As compared with controls, the risk of myocardial infarction was not increased within 1 year after discharge for total hip replacement [adj. hazard ratio = 0.83, 95% confidence interval: 0.60–1.16] or total knee replacement [adj. hazard ratio = 0.97, 95% confidence interval: 0.63–1.48]. The corresponding cumulative incidence was 0.4% 1 year after total hip/knee replacement discharge. Furthermore, the hazard ratio of myocardial infarction was not different between patients exposed to total hip/knee replacement and controls, when the surgery was performed more than 1 year ago.

Conclusion
The hazard ratio of acute myocardial infarction was not increased in the year following discharge for total hip/knee replacement surgery or in the subsequent period, as compared with controls without surgery. The incidence of post-discharge acute myocardial infarction was low, which is possibly related to the current treatment regimen, including low-molecular-weight-heparins for an extended duration of 6 weeks and early revalidation after surgery.

Introduction
Joint replacement surgery provides relief of pain and improvement of function for a large number of patients with treatment-refractory, end-stage hip or knee osteoarthritis (OA). The number of these procedures will continue to increase in the Netherlands due to demographic changes and increase in overweight. Total hip/knee replacements (THR/TKR) have been associated with peri- and postoperative acute myocardial infarction (MI). Potential causes include bone marrow embolism upon surgical invasion of the femoral medullary canal, or haemodynamic stressors such as anaesthesia, blood loss, fluid shifts, arrhythmias and hypoxia. However, antithrombotic drugs are commonly used in these patients and may have the potential to decrease the risk of acute MI. Furthermore, limited exercise during the revalidation period or increased exercise (mobility) as a result of a successful operation may influence the postoperative acute MI risk in the longer term.

Previous studies have shown conflicting postoperative MI rates, ranging from 0.1% to 1.2% within 90 days after surgery. This may be explained by differences in baseline characteristics, study design and the operational definition of acute MI. A large population-based cohort study showed an increased risk of MI within 2 weeks after THR (25 times) or TKR (31 times) surgery as compared with matched controls. However, no study determined the risk of acute MI in patients with THR/TKR versus matched controls in the period following discharge. In the past decade, clinical guidelines have encouraged discharging patients with THR/TKR earlier from hospitals to reduce costs. To what

Licensee OA Publishing London 2013. Creative Commons Attribution Licence (CC-BY)

For citation purposes: Klop C, de Vries F, Lalmohamed A, Leufkens HGM, Bijlsma JWJ, Welsing PMJ. Risk of myocardial infarction in Dutch patients following discharge for total hip/knee replacement and matched controls: a population-based cohort study. OA Epidemiology 2013 Jun 04;1(1):6.

Competing interests: none declared. Conflict of Interests: declared in the article. All authors contributed to the conception, design, and writing of the manuscript, as well as read and approved the final manuscript.
extent this earlier discharge has influenced post-discharge acute MI events remains unknown. Therefore, we aim to determine the excess risk of acute MI shortly after discharge for THR/TKR surgery as compared with matched controls without surgery for the Dutch setting. In addition, we have examined this risk for a prolonged follow-up period after discharge (<1 year; ≥1 year).

**Materials and methods**

**Data source**

Utilising the Dutch PHARMO Record Linkage System (PHARMO RLS), we conducted a population-based retrospective cohort study. The PHARMO RLS (Institute for Drug Outcome Research) is a database that contains the pharmacy dispensing data of approximately three million community-dwelling inhabitants in the Netherlands. These pharmacy dispensing records are linked to the Dutch national hospitalisation registry. Diagnoses are coded according to the International Classification of Disease, 9th revision codes (ICD-9). PHARMO RLS has been used before for the exposure to THR/TKR surgery14 and the outcome of acute MI5,16.

**Study population**

We have included all patients aged ≥40 years with an elective primary THR or TKR (ICD-9 procedure code; THR 81.51, TKR 81.54) between 1 January 2000 and 31 December 2009. Each patient who underwent primary THR or TKR surgery was matched by age, gender and geographical location to a maximum of three patients who did not undergo this surgery using the incidence density sampling technique. The index date was defined as the discharge date for THR/TKR and was the same for the matched unexposed patients. To derive a study population with an elective THR/TKR due to OA, we have excluded patients with a history or a record within 3 months after the index date for fracture of the hip or knee, rheumatoid arthritis (including exposure to disease-modifying antirheumatic drugs or biologics specific for rheumatoid arthritis) and osteoporosis drugs. Finally, we have excluded patients with a previous MI within 6 weeks before the index date, to minimise the possibility of a recurrent MI. This was done for both patients exposed to THR/TKR and controls.

**Study outcomes**

All patients were followed up from the index date until the occurrence of acute MI (classified using ICD-9 code: 410), death, hip or knee replacement revision, migration or end of the study period (31 December 2009), whichever came first. Acute MIs that occur during hospitalisation for THR/TKR surgery are not properly registered in the Dutch national hospitalisation registry. Therefore, occurrence of an acute MI was defined as ‘a hospital admission after the index date (discharge for THR/TKR surgery in the exposed cohort or matched dummy index date for the unexposed cohort)’.

**Definition of covariates**

We considered age, male gender, a history of cardiovascular disease (ischaemic heart disease (IHD) including an acute MI ≥6 weeks before the index date or ≥2 prescriptions of nitrates in the past, congestive heart failure, vascular disease), chronic kidney disease, cerebrovascular disease and malignancies as potential determinants of acute MI or confounders for the association between THR/TKR and the occurrence of an acute MI. Furthermore, a prescription for thiazide diuretics, loop diuretics, β blockers, calcium-channel blockers, antiarrhythmic drugs, rennin–angiotensin–aldosterone inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), statins, vitamin K antagonists, antiplatelet drugs, other antithrombotic drugs including heparins, direct thrombin inhibitors and thrombolytic agents, oestrogen-containing drugs, inhaled β-2-agonists17,18 and anti-diabetic drugs within 6 months were also considered as determinants and potential confounders for the association.

**Statistical analysis**

To study the association between the THR/TKR and the occurrence of an acute MI, the total follow-up time was divided into three periods—<6 weeks, 6 weeks to <1 year and ≥1 year. Using the PHREG procedure from SAS 9.1.3, we calculated the hazard ratios (HRs) for risk of acute MI among patients with THR/TKR versus the matched unexposed patients for each previously mentioned time period separately. The presence of potential determinants or confounders was evaluated before and during follow-up, and confounders were added to the final model if they independently changed the β coefficient for THR/TKR by at least 5%. Additionally, Kaplan–Meier plots were used to present the cumulative incidence rates of acute MI over time (follow-up of 1 year) for patients and controls.

Potential effect modifiers were evaluated for each time period. We evaluated potential effect modifiers by including an interaction term into the model (THR or TKR × covariate).

To identify the potential determinants of acute MI in the previously mentioned time intervals in patients with THR or TKR, we included only the patients with THR/TKR. Potential determinants of acute MI among patients with THR/TKR were identified when they were significantly (p < 0.05) associated with the outcome in a full regression model (including all covariates into the model).

**Results**

We have identified 22,191 patients who underwent primary elective total joint replacement surgery that was most likely to be the result of OA (THR: 13,952 patients, TKR: 8,239 patients).
Due to a small number of events in the first 6 weeks after discharge for THR/TKR surgery, we have merged the <6 week and 6 weeks to <1 year periods into a 1-year period. As compared with the matched control subjects, the 1-year HR of acute MI was not increased after exposure to THR [adjusted (adj.) HR 0.83, 95% confidence interval (CI): 0.60–1.16] or TKR surgery (adj. HR 0.97, 95% CI: 0.63–1.48). Similar HRs were seen when these procedures were performed more than 1 year ago (Table 2). Among patients who have undergone elective THR, 0.36% showed to have an acute MI within 1 year post-THR discharge. The corresponding cumulative incidence of the population-based matched controls was 0.44% (Figure 1). Similarly, among patients who have undergone elective TKR, 0.38% showed to have an acute MI within 1 year post-TKR discharge while 0.40% of the matched controls developed an acute MI in this period (Figure 2). In addition, we did not find any effect modifiers for the relationship between THR/TKR surgery and the risk of acute MI for both follow-up periods (Table 2).

Among patients exposed to THR, the 1-year HR of acute MI was almost three-fold higher for patients with a history of IHD or having at least two prescriptions for organic nitrates in the past (full model HR 2.98, 95% CI: 1.41–6.31) (Table 3). Among patients exposed to TKR, we did not identify any significant determinant for the 1-year risk of acute MI (Table 3). When we sought for potential determinants of acute MI among patients with THR after 1 year of follow-up (THR surgery was performed more than 1 year ago), a history of IHD lost significance. However, for this follow-up period, age older than 60 years and male gender appeared to be significant determinants of acute MI. Among patients exposed to TKR, significant determinants included male gender and use of anti-diabetic drugs within 6 months.
Table 1. Baseline characteristics of patients with THR/TKR and matched unexposed patients.

| Characteristic                          | Total hip replacement | Total knee replacement |
|----------------------------------------|-----------------------|------------------------|
|                                        | Exposed | Unexposed | p value* | Exposed | Unexposed | p value* |
| Mean follow-up time (years, SD)        |         |           |          |         |           |          |
|                                        | n = 13,952 | n = 30,795 |          | n = 8,239 | n = 17,069 |          |
|                                        |          |           |          |          |           |          |
| Males (%)                              | 36.6    | 36.1      | 0.784    | 34.9    | 34.6      | 0.273    |
| Mean age (years, SD)                   | 68.5 (10.1) | 68.8 (10.3) |          | 68.4 (9.9) | 68.3 (10.0) |          |
| Mean THR/TKR hospital stay (days, SD)  | 8.4 (6.5) |           |          | 8.2 (6.4) |           |          |

Disease history (%)

- IHD or ≥2 prescriptions of organic nitrates: Exposed 9.1, Unexposed 9.6, p = 0.066
- Congestive heart failure: Exposed 0.6, Unexposed 1.0, p < 0.001
- Vascular disease: Exposed 0.9, Unexposed 1.0, p = 0.347
- Cerebrovascular disease: Exposed 1.5, Unexposed 1.7, p = 0.104
- Chronic kidney disease: Exposed 0.1, Unexposed 0.2, p = 0.158
- Malignancy: Exposed 4.3, Unexposed 4.0, p = 0.103

Drug use 6 months before index date (%)

- Paracetamol: Exposed 10.4, Unexposed 4.3, p < 0.001
- NSAIDs: Exposed 51.5, Unexposed 17.3, p < 0.001
- Opioids (tramadol or stronger): Exposed 13.4, Unexposed 3.8, p < 0.001
- Antithrombotic agents: Exposed 14.2, Unexposed 0.3, p < 0.001
- RAAS inhibitors: Exposed 24.0, Unexposed 22.4, p < 0.001
- Thiazide diuretics: Exposed 20.1, Unexposed 17.1, p < 0.001
- Loop diuretics: Exposed 7.3, Unexposed 7.8, p = 0.06
- β Blockers: Exposed 20.6, Unexposed 19.4, p = 0.05
- Calcium channel antagonists: Exposed 12.2, Unexposed 11.1, p < 0.001
- Antithrombotic agents: Exposed 2.0, Unexposed 1.8, p = 0.163
- Statins: Exposed 19.2, Unexposed 19.1, p = 0.934
- Bronchodilators: Exposed 9.6, Unexposed 10.4, p = 0.05
- Anti-diabetics: Exposed 8.5, Unexposed 10.4, p < 0.001
- Estrogen-containing drugs: Exposed 3.8, Unexposed 3.5, p = 0.07

IHD, ischaemic heart disease; NSAIDs, non-steroidal anti-inflammatory drugs; RAAS, renin-angiotensin-aldosterone system; SD, standard deviation; THR, total hip replacement; TKR, total knee replacement.

*p values for differences between exposed/non-exposed groups have been obtained using Chi-square tests for proportions and independent samples t-tests for means.

Discussion

This study shows that the HR of acute MI is not increased in the year following discharge after THR or TKR surgery or in the subsequent period, as compared with population-based matched controls. A significant determinant of the 1-year acute MI risk included a history of IHD (or ≥2 prescriptions of organic nitrates) among patients exposed to THR, while there were no significant determinants identified among patients exposed to TKR. When surgery was performed more than 1 year ago, significant determinants of acute MI included older age (>60 years) and male gender among patients exposed to THR, while use of anti-diabetics within 6 months and male gender were determinants among patients exposed to TKR.
exposed to TKR. However, no modification of the relationship between THR or TKR surgery and acute MI could be identified for both follow-up periods. This indicates that patients with a higher risk of acute MI do not have a surgery-induced excess risk after discharge for elective THR or TKR surgery.

To our knowledge, this is the first Dutch study that compared the risk of acute MI following THR or TKR surgery with population-based matched controls directly after discharge from the hospital and for a long-term follow-up period. The other large study that has evaluated the excess risk of acute MI in a Danish cohort of patients, found an elevated risk of acute MI for patients exposed to THR (25 times higher) and TKR (31 times higher) when compared with matched controls within 2 weeks after surgery. Our study could detect very few events within 2 weeks after discharge for THR and TKR surgery (Figures 1 and 2). However, the first study also included acute MIs that occurred during hospitalisation for THR/TKR surgery. A US observational study within patients reported an incidence rate for acute MI of 0.4% within 30 days from surgery. This study reported a median time to acute MI of 1 day and 83% of all recorded MIs occurred within 3 days after surgery. Since the mean duration of hospital stay was, respectively, 8.4 days and 8.2 days for THR and TKR surgery in the present study, this may explain the lower cumulative incidence rate for acute MI and no increased risk as compared with controls without surgery. Studies

| Table 2. Effect modification of the hazard ratio of acute MI following discharge for joint replacement surgery versus matched unexposed controls. |
|-----------------------------------------------|
| **Total hip replacement surgery** | **Total knee replacement surgery** |
| | | <1 year | ≥1 year | <1 year | ≥1 year |
| | Adj. HR (95% CI)* | Adj. HR (95% CI)* | Adj. HR (95% CI)* | Adj. HR (95% CI)* |
| Overall (all patients) | 0.83 (0.60–1.16) | 1.04 (0.86–1.26) | 0.97 (0.63–1.48) | 0.86 (0.64–1.15) |
| By gender |  |
| Males | 0.92 (0.64–1.33) | 1.15 (0.89–1.48) | 1.06 (0.65–1.73) | 0.94 (0.64–1.39) |
| Females | 0.75 (0.51–1.09) | 0.94 (0.72–1.22) | 0.88 (0.54–1.45) | 0.79 (0.54–1.15) |
| By age |  |
| <60 years | 0.83 (0.51–1.33) | 0.94 (0.60–1.50) | 1.02 (0.55–1.88) | 0.95 (0.52–1.74) |
| >60 years | 0.92 (0.72–1.18) | 1.05 (0.86–1.29) | 0.90 (0.65–1.25) | 0.84 (0.62–1.15) |
| By disease history |  |
| No IHD or ≥2 organic nitrate prescriptions | 0.91 (0.65–1.29) | 1.13 (0.91–1.40) | 1.10 (0.70–1.72) | 0.98 (0.70–1.35) |
| IHD or ≥2 organic nitrate prescriptions | 0.65 (0.41–1.04) | 0.81 (0.55–1.17) | 0.68 (0.36–1.28) | 0.61 (0.36–1.03) |
| By drug use in the 6 months before |  |
| No NSAIDs | 0.83 (0.59–1.16) | 1.04 (0.85–1.27) | 1.01 (0.66–1.56) | 0.89 (0.66–1.20) |
| NSAIDs | 0.83 (0.36–1.94) | 1.04 (0.46–2.37) | 0.19 (0.02–1.54) | 0.17 (0.02–1.33) |
| No β blockers | 0.85 (0.60–1.20) | 1.06 (0.84–1.33) | 0.97 (0.61–1.53) | 0.86 (0.61–1.20) |
| β Blockers | 0.81 (0.53–1.23) | 1.01 (0.74–1.38) | 0.98 (0.56–1.71) | 0.87 (0.55–1.37) |
| No anti-diabetics | 0.88 (0.62–1.23) | 1.10 (0.90–1.36) | 0.89 (0.57–1.38) | 0.78 (0.56–1.08) |
| Anti-diabetics | 0.61 (0.36–1.04) | 0.77 (0.48–1.21) | 1.39 (0.73–2.70) | 1.22 (0.71–2.11) |
| By antithrombotic agents in the 6 months before (ref = no use 6 months before) |  |
| No anticoagulant use | 1.12 (0.84–1.49) | 1.17 (0.92–1.48) | 1.06 (0.72–1.57) | 0.85 (0.60–1.22) |
| Vitamin K antagonist only | 0.70 (0.41–1.21) | 0.74 (0.43–1.26) | 0.35 (0.13–0.94) | 0.28 (0.10–0.76) |
| Anti-platelet drugs only | 0.92 (0.66–1.29) | 0.96 (0.71–1.29) | 1.35 (0.87–2.08) | 1.08 (0.72–1.63) |
| Others/mixed use | 0.72 (0.34–1.53) | 0.75 (0.35–1.64) | 0.85 (0.27–2.62) | 0.68 (0.21–2.20) |

*Adjusted for IHD, cardiovascular drugs (RAAS inhibitors, thiazide diuretics, loop diuretics, β blockers and calcium-channel blockers), anticoagulants, statins and anti-diabetics.

IHD, ischemic heart disease; MI, myocardial infarction; NSAIDs, non-steroidal anti-inflammatory drugs.
Table 3. Determinants of acute MI after discharge within THR/TKR patients.

| Drug use 6 months before (ref = no use 6 months before) | Total hip replacement surgery | Total knee replacement surgery |
|---------------------------------------------------------|-----------------------------|-------------------------------|
|                                                        | <1 year (HR (95% CI)*        | ≥1 year (HR (95% CI)*        |
|                                                        | ≥1 year (HR (95% CI)*        | ≥1 year (HR (95% CI)*        |
| Males (ref = females)                                   | 1.53 (0.86–2.71)            | 2.48 (1.77–3.47)             |
| Age (ref ≤60 years)                                     | 1.07 (0.51–2.26)            | 2.30 (1.33–3.98)             |
| >60 years                                               | 3.79 (0.90–16.1)            | 1.52 (0.74–3.13)             |
| Disease history (ref = no history)                      |                             |                               |
| IHD or ≥2 organic nitrate prescriptions                  | 2.98 (1.41–6.31)            | 1.01 (0.62–1.64)             |
| Drug use 6 months before (ref = no use 6 months before) |                             |                               |
| NSAIDs                                                  | 1.01 (0.42–2.39)            | 1.75 (0.94–3.28)             |
| β Blockers                                              | 1.25 (0.64–2.44)            | 1.37 (0.93–2.01)             |
| Anti-diabetics                                          | 0.72 (0.25–2.07)            | 1.22 (0.75–1.97)             |
| Others/mixed use                                        | 1.12 (0.55–2.28)            | 0.63 (0.20–2.01)             |

*Full model included: gender, age (<60 years; ≥60 years); history of IHD, IHD or ≥1 prescription(s) for organic nitrates, IHD or ≥2 prescriptions for organic nitrates, heart failure, vascular disease, malignancy, cerebrovascular disease; a prescription of NSAIDs, anti-arrhythmic drugs, thiazide diuretics, loop diuretics, β blockers, RAAS inhibitors, calcium channel blockers, anti-diabetics, vitamin K antagonists, anti-platelet drugs (others/mixed use of antithrombotic drugs) in the 6 months before.

IHD, ischaemic heart disease; MI, myocardial infarction; NSAIDs, non-steroidal anti-inflammatory drugs; THR, total hip replacement; TKR, total knee replacement.

that have determined the readmission rates for acute MI following TKR or THR surgery showed incidence rates between 0.1%5 and 1.0%10 within 90 days after surgery. Our findings are in line with the lower rate of 0.1% that was reported for 15,943 American TKR patients with a very similar age and sex distribution (mean age 68 years, 38% was male) as compared with TKR patients in the present study5.

The biological mechanism for an elevated acute MI risk shortly after THR or TKR surgery may be explained by bone marrow embolisation upon the surgical invasion of the femoral medullary canal or by haemodynamic stressors (such as anaesthesia, blood loss, fluid shifts, arrhythmias and hypoxia)2,3. In addition, the amount of exercise (time to initiation of the revalidation period or increased mobility after a successful operation) and pharmacological treatment may influence this risk for prolonged periods after THR or TKR surgery. In the Netherlands, 87% of all patients who undergo THR or TKR surgery are treated with low-molecular-weight heparins (LMWHs) and 13% are treated with fondaparinux. This treatment is administered for a prolonged out-of-hospital period of 6 weeks or longer in a substantial number of THR/TKR patients (91%)19. Similarly, Danish guidelines and the American College of Chest Physicians recommend thromboprophylaxis (predominantly with LMWHs) to be extended beyond 10 days and up to 35 days after THR/TKR surgery13,20. A meta-analysis of randomised clinical trials has shown that extended, out-of-hospital, administration of LMWHs for 6 weeks resulted in a significantly reduced risk of thromboembolic events21. In addition, these agents were able to significantly reduce the risk of MI during the first month of therapy in patients (n = 1049) with unstable coronary artery disease4. Another trial showed that the 2-year incidence of recurrent acute MI was significantly reduced with LMWHs as compared with placebo in elderly patients22.

Strengths of this study include its population-based design, large sample size and completeness of follow-up (approximately 4 years for both patients exposed to THR/TKR and matched controls). We also had access to reliable data on outpatient prescription drugs, which made adjustment for medication use possible (e.g. NSAIDs, which may have the potential to increase the risk of acute MI23). Finally, we were able to interpret the magnitude of acute MI incidence as compared with
the general population with the inclusion of a matched population-based control cohort. A drawback of this study includes the incomplete capture of acute MIs that have occurred during the hospital admission period for THR or TKR surgery (mean duration of 8 days). This is due to an unreliable registration because hospitals are not obliged to register these events during the admission period for the major indication/procedure (THR/TKR surgery). However, there is also a good rationale for determining the excess risk of acute MI following discharge for THR/TKR. In the past decade, clinical guidelines have encouraged discharging THR/TKR patients earlier from hospitals to reduce costs. To what extent this earlier discharge has influenced post-surgical (in particular post-discharge) acute MI events was previously unknown. Moreover, we had no data on un-hospitalised fatal acute MIs. Those events are not registered in the Dutch national hospitalisation registry and accounts for 40% of all acute MI cases in the Netherlands. This may have led to an underestimation of the true acute MI incidence in our study population. However, we do not expect that the number of fatal, out-of-hospital, acute MIs would vary differentially between patients exposed to THR/TKR and controls. In addition, healthy user bias cannot be ruled out since Dutch physicians and orthopaedics may predominantly select patients who are healthy enough to undergo this type of surgery. Last, we had no information about some general risk factors of acute MI such as body mass index (BMI), smoking, blood pressure and in-hospital use of antithrombotic therapy. Some of these factors may be somewhat higher in patients who are exposed to THR/TKR due to OA (e.g. BMI). This could have masked an actual increased risk of acute MI among patients with THR/TKR patients as compared with controls. However, selection for surgery might decrease this effect. Also, as explained earlier, a very high percentage of patients who undergo THR or TKR surgery are treated with LMWHs, which is initiated within 6 h post-operatively and used (out-of-hospital) for an extended duration of 6 weeks.

Conclusion
This study shows a very low readmission rate for acute MI within 6 weeks after discharge for THR or TKR surgery. In addition, the risk of acute MI was not increased in the year after discharge or in the subsequent period, as compared with patients who have not undergone this surgery. The low risk of acute MI after discharge for THR or TKR surgery in the Netherlands is possibly related to the current treatment regimen including LMWHs for an extended out-of-hospital period and early revalidation after surgery.

Conflict of interest
The Division of Pharmacoepidemiology & Clinical Pharmacology (employing C.K., F.V., A.L.) has received unrestricted funding from the Netherlands Organisation for Health Research and Development (ZonMW), the Dutch Health Care Insurance Board (CVZ), the Royal Dutch Pharmacists Association (KNMP), the private-public funded Top Institute Pharma (www.tifpharma.nl), (includes co-funding from universities, government, and industry), the EU Innovative Medicines Initiative (IMI), the EU 7th Framework Program (FP7) and the Dutch Ministry of Health and industry (including GlaxoSmithKline, Pfizer and others).

Bert Leufkens is a researcher at the World Health Organization Collaborating Centre for Pharmaceutical Policy & Regulation, which receives no direct funding or donations from private parties, including pharma industry. Research funding from public-private partnerships, for example IMI, TI Pharma (www.tifpharma.nl) is accepted under the condition that no company-specific product or company-related study is conducted. The Centre has received unrestricted research funding from public sources, for example Netherlands Organisation for Health Research and Development (ZonMW), the Dutch Health Care Insurance Board (CVZ), EU 7th Framework Program (FP7), Dutch Medicines Evaluation Board (MEB) and the Dutch Ministry of Health.

Abbreviations list
BMI, body mass index; CI, confidence interval; HR, hazard ratio; IHHD, ischemic heart disease; LMWH, low-molecular-weight heparin; MI, myocardial infarction; NSAID, non-steroidal anti-inflammatory drug; OA, osteoarthritis; THR/TKR, total hip/knee replacement.

References
1. Otten R, van Roermund PM, Picavet HS. Trends in the number of knee and hip arthroplasties: considerably more knee and hip prostheses due to osteoarthritis in 2030. Ned Tijdschr Geneeskd. 2010; 154:A1534.
2. Hofmann S, Huemer G, Kratodwill C, Koller-Strameetz J, Hopf R, Schlag G, et al. Pathophysiology of fat embolisms in orthopedics and traumatology. Orthopäde. 1995 Apr;24(2):84–93.
3. Eagle KA, Berger PB, Callans H, Chaitman BR, Ewy GA, Fleischmann KE. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol. 2002 Feb;39(3):542–53.
4. Flagmin and Fast Revascularisation during lnStability in Coronary artery disease (FRISC II) investigators. Long-term low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomized multicentre study. Lancet. 1999 Aug;354(9180): 701–7.
Research Study

Khopad M, Inacio M, Paxton EW, Bini SA, Namba RS, Burchette RJ, et al. Knee replacement: epidemiology, outcomes, and trends in Southern California; 17,080 replacements from 1995 through 2004. Arch Orthop. 2008 Dec;79(6):812–19.

Singh JA, Jensen MR, Harmsen WS, Gabriel SE, Lewallen DG. Cardiac and thromboembolic complications and mortality in patients undergoing total hip and total knee arthroplasty. Ann Rheum Dis. 2011 Dec;70(12):2082–88.

Mantilla CB, Wass CT, Goodrich KA, Johanns CJ, Kool ML, Zhu X, et al. Risk of perioperative myocardial infarction and mortality in patients undergoing hip or knee arthroplasty: the role of anemia. Transfusion. 2011 Jan;51(1):82–91.

Lalmohamed A, Vestergaard P, Klop C, Grove EL, de Boer A, Leufkens HG, et al. Timing of acute myocardial infarction in patients undergoing total hip or knee replacement: a nationwide cohort study. Arch Intern Med. 2012 Sep;172(16):1229–35.

Klop C, de Vries E, Lalmohamed A, Mastbergen SC, Leufkens HG, Noort-van der Laan WH, et al. COX-2 selective NSAIDs and risk of hip or knee replacements: a population-based case-control study. Calcif Tissue Int. 2012 Dec;91(6):387–94.

Pulido L, Parvizi J, Macquibeny M, Sharkey PF, Purtilt JJ, Rothman RH. In hospital complications after total joint arthroplasty. J Arthroplasty. 2008 Sep;23(6 Suppl 1):139–45.

Parvizi J, Mui A, Purtilt JJ, Sharkey PF, Hozack WJ, Rothman RH. Total joint arthroplasty: when do fatal or near-fatal complications occur? J Bone Joint Surg Am. 2007 Jan;89(1):27–32.

Mahomed NN, Barrett J, Katz JN, Baron JA, Wright J, Losina E. Epidemiology of total knee replacement in the United States Medicare population. J Bone Joint Surg Am. 2005 Jun;87(6):1222–8.

Mantilla CB, Horlocker TT, Schroeder DR, Berry DJ, Brown DL. Frequency of myocardial infarction, pulmonary embolism, deep venous thrombosis and death following primary hip or knee arthroplasty. Anaesthesiology. 2002 May; 96(5):1140–6.

Geerts WH, Bergqvist D, Pineo GE, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed.). Chest. 2008 Jun;133(6 Suppl):381S–453S.

Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet. 2001 Jul;358(9275):9–15.

Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group. Lancet. 1980 Nov;2(8202):989–94.

Garcia Rodríguez LA, González-Pérez A. NSAIDs and the risk of acute myocardial infarction. Nat Clin Pract Rheumatol. 2007 Apr;3(4):202–3.

Koel HL, Bruin A de, Gast A, Gevers E, Kardaun JW, Reitsma JB, et al. Incidence of first acute myocardial infarction in the Netherlands. Neth J Med. 2007 Dec;65(11):434–41.

Licensee OA Publishing London 2013. Creative Commons Attribution Licence (CC-BY)

For citation purposes: Klop C, de Vries E, Lalmohamed A, Leufkens HGM, Bijlsma JWJ, Welsing PMJ. Risk of myocardial infarction in Dutch patients following discharge for total hip/knee replacement and matched controls: a population-based cohort study. OA Epidemiology 2013 Jun 04;1(1):6.